COMMUNIQUÉ DE PRESSE

par Bio-Rad Laboratories GmbH (isin : DE0007165607)

SARTORIUS AG: Florian Funck appointed CFO of Sartorius

EQS-News: SARTORIUS AG / Key word(s): Personnel
SARTORIUS AG: Florian Funck appointed CFO of Sartorius

03.08.2023 / 19:09 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, August 3, 2023

Florian Funck appointed CFO of Sartorius

  • New CFO to take over as of April 2024

At today’s meeting, the Supervisory Board of Sartorius AG appointed Dr. Florian Funck as Chief Financial Officer (CFO) and member of the Sartorius Executive Board, effective April 1, 2024. He succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023.

Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck, who holds a Ph.D. in Business Administration, is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann’s departure and until Funck takes over, Sartorius CEO Dr. Joachim Kreuzburg will assume these responsibilities on an interim basis.

"We are very pleased to welcome Florian Funck as the new CFO of Sartorius in a few months’ time. With his long and extensive experience in finance and M&A transactions, as well as his team-oriented leadership style, he is the ideal CFO for the further implementation of our growth and innovation strategy," said Dr. Lothar Kappich, Chairman of the Supervisory Board. "I would also like to again thank our outgoing CFO Rainer Lehmann for his many contributions to Sartorius and wish him a good start in his new role."

 

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.

 

A profile of Sartorius

The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.

 

 

Contacts

Petra Kirchhoff

Head of Corporate Communications & Investor Relations

+49 551 308 1686

petra.kirchhoff@sartorius.com

 

 

Follow Sartorius on Twitter and LinkedIn.

 

 



03.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language:English
Company:SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone:+49.(0)551-308.0
Fax:+49.(0)551-308.3289
E-mail:info@sartorius.com
Internet:www.sartorius.com
ISIN:DE0007165607, DE0007165631
WKN:716560 , 716563
Indices:DAX, TecDAX
Listed:Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:1695833

 
End of NewsEQS News Service

1695833  03.08.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1695833&application_name=news&site_id=symex
Voir toutes les actualités de Bio-Rad Laboratories GmbH